Envafolimab Explained

Type:mab
Mab Type:scFv
Target:PD-L1
Class:Antineoplastic agent
Atc Suffix:Not available
Cas Number:2102192-68-5
Pubchem:381609252
Drugbank:DB15769
Unii:ES1M06M6QH

Envafolimab is an anti-PD-L1 nanobody used in cancer immunotherapy.[1] It has been approved in China for the treatment of microsatellite instability-high (MSI-H) or MisMatch Repair deficient (dMMR) solid tumours.[2] Envafolimab (KN035) has obtained the U.S. FDA's orphan drug designation for advanced biliary tract cancer.

Notes and References

  1. Web site: Envafolimab - Alphamab Oncology/Ascletis/3D Medicine . AdisInsight . Springer Nature Switzerland AG .
  2. Markham A . Envafolimab: First Approval . Drugs . 82 . 2 . 235–240 . February 2022 . 35122636 . 10.1007/s40265-022-01671-w . 246534311 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Envafolimab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.